LM NEWS 24
LM NEWS 24

Covaxin Can Neutralise Delta, Omicron Variants: Bharat Biotech

Hyderabad-based Bharat Biotech on Wednesday claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.

In a statement, Bharat Biotech said, “Results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin, neutralized the SARS-CoV-2 Omicron and Delta variants.”
It also mentioned that earlier studies demonstrated the neutralizing potential of Covaxin against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa.

The study will be published on the pre-print server, medRXiv, shortly.

Sera samples from individuals who received a booster of Covaxin were observed to be effective in neutralizing Omicron and Delta variants on a live virus neutralization assay.

The Hyderabad based company claimed that the neutralization activity of Covaxin boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant and found more than 90 per cent of all individuals boosted with Covaxin showed neutralizing antibodies.

All participants received an initial two-dose schedule of Covaxin on Day 0 and Day 28.

“As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern,” said Mehul Suthar, PhD Assistant Professor, Emory Vaccine Center who led the laboratory analysis.

Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations, said the statement.

“We are in a continuous state of innovation and product development for Covaxin. The positive neutralization responses against the Omicron and Delta variants validate our hypothesis of a multi-epitope vaccine generating both humoral and cell-mediated immune responses. Our goals of developing a global vaccine against COVID-19 have been achieved with the use of Covasxin as a universal vaccine for adults and children,” said Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech.

“The global impact of Omicron shows us that the fight against COVID-19 continues, and we are encouraged that these data demonstrate the value of Covaxin as a primary and booster vaccine. These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants and mutations,” said Dr Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc. (ANI)

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are essential in order to enable you to move around the website and use its features. Without these cookies basic services cannot be provided.

Cookie generated by applications based on the PHP language. This is a general purpose identifier used to maintain user session variables. It is normally a random generated number, how it is used can be specific to the site, but a good example is maintaining a logged-in status for a user between pages.
  • PHPSESSID

Used on sites built with Wordpress. Tests whether or not the browser has cookies enabled
  • wordpress_test_cookie

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
0
Would love your thoughts, please comment.x
()
x